Table 1.

Summary of dose coefficients for both Effective Dose and Organ Equivalent Dose (Sv per Bq intake) for all 21 exposure scenarios considered in this study.

Exposure				Solubility		Effective dose	Equivalent dose 30 days to lungs	Equivalent dose 30 days to RBM	Equivalent dose 30 days to thyroid
Scenario	Radionuclide	Intake	AMAD	Class	fA	(Sv/Bq-intake)	(Sv/Bq-intake)	(Sv/Bq-intake	(Sv/Bq-intake)
1	Am-241	Inhal	1 µm	Type M	0.0005	3.90 × 10−5	1.70 × 10−5	7.20 × 10−8
2	Am-241	Inhal	5 µm	Type M	0.0005	2.70 × 10−5	1.30 × 10−5	7.40 × 10−8
3	Am-241	Inges			0.0005	2.00 × 10−7	3.50 × 10−11	1.20 × 10−9
4	Co-60	Inhal	1 µm	Type M	0.10	9.60 × 10−9	1.90 × 10−8	6.60 × 10−10
5	Co-60	Inhal	1 µm	Type S	0.05	2.90 × 10−3	2.20 × 10−8	6.90 × 10−10
6	Co-60	Inhal	5 µm	Type M	0.10	7.10 × 10−9	1.50 × 10−8	5.60 × 19−10
7	Co-60	Inhal	5 µm	Type S	0.05	1.70 × 10−8	1.70 × 10−8	5.40 × 10−10
8	Co-60	Inges			0.10	3.40 × 10−9	2.10 × 10−10	5.70 × 10−10
9	Cs-137	Inhal	1 µm	Type F	1.00	4.80 × 10−9	8.00 × 10−10	8.00 × 10−10
l0	Cs-137	Inhal	5 µm	Type F	1.00	6.70 × 10−9	1.10 × 10−9	1.10 × 10−9
11	Cs-137	Inges			1.00	1.30 × 10−8	2.20 × 10−9	2.30 × 10−9
12	I-131	Inhal	1 µm	Type F	1.00	7.60 × 10−9	5.70 × 10−11		1.40 × 10−7
12	I-131	Inhal	5 µm	Type F	1.00	1.10 × 10−8	7.80 × 10−11		2.00 × 10−7
14	I-131	Inges			1.00	2.20 × 10−8	9.70 × 10−11		4.00 × 10−7
15	Ir-192	Inhal	1 µm	Type F	0.01	1.80 × 10−9	4.50 × 10−10	4.50 × 10−10
16	Ir-192	Inhal	1 µm	Type M	0.01	4.90 × 10−9	2.10 × 10−8	2.50 × 10−10
17	Ir-192	Inhal	1 µm	Type S	0.01	6.20 × 10−9	2.40 × 10−8	2.30 × 10−10
18	Ir-192	Inhal	5 µm	Type F	0.01	2.20 × 10−9	5.40 × 10−10	5.20 × 10−10
19	Ir-192	Inhal	5 µm	Type M	0.01	4.10 × 10−9	1.70 × 10−8	2.20 × 10−10
20	Ir-192	Inhal	5 µm	Type S	0.01	4.90 × 10−9	2.00 × 10−8	1.90 × 10−10
21	Ir-192	Inges			0.01	1.40 × 10−9	3.20 × 10−11	1.90 × 10−10